@article{Liu2019,
title = {Effects of lactobacillus plantarum PS128 on children with autism spectrum disorder in Taiwan: A randomized, double-blind, placebo-controlled trial},
author = {Y -W Liu and M T Liong and Y -C E Chung and H -Y Huang and W -S Peng and Y -F Cheng and Y -S Lin and Y -Y Wu and Y -C Tsai},
url = {https://www.scopus.com/inward/record.uri?eid=2-s2.0-85064817846&doi=10.3390%2fnu11040820&partnerID=40&md5=ca04462e8710198b821b44f8e73061f3},
doi = {10.3390/nu11040820},
issn = {20726643},
year = {2019},
date = {2019-01-01},
journal = {Nutrients},
volume = {11},
number = {4},
publisher = {MDPI AG},
abstract = {This four-week, randomized, double-blind, placebo-controlled study investigated the effects of Lactobacillus plantarum PS128 (PS128) on boys with autism spectrum disorder (ASD) aged 7-15 in Taiwan. All subjects fulfilled the criteria for ASD diagnosis of DSM-V and the Autism Diagnostic Interview-Revised (ADI-R). Questionnaires used for the primary outcome measure include the Autism Behavior Checklist-Taiwan version (ABC-T), the Social Responsiveness Scale (SRS) and the Child Behavior Checklist (CBCL). The Swanson, Nolan, and Pelham-IV-Taiwan version (SNAP-IV) and the Clinical Global Impression-improvement (CGI-I) were used for the secondary outcome measure. The results showed that PS128 ameliorated opposition/defiance behaviors, and that the total score of SNAP-IV for younger children (aged 7−12) improved significantly compared with the placebo group. Additionally, several elements were also notably improved in the PS128 group after 28-day consumption of PS128. Further studies are needed to better clarify the effects of PS128 for younger children with ASD on broader symptoms. © 2019 by the authors. Licensee MDPI, Basel, Switzerland.},
note = {cited By 4},
keywords = {Aberrant Behavior Checklist Taiwan version, Adolescent, Age, Age Factors, Aggression, Anxiety, Article, Attention Deficit Disorder, Autism, Autism Behavior Checklist, Autism Diagnostic Interview Revised, Autism Spectrum Disorders, Child Behaviour, Child Behaviour Checklist, Children, Clinical Global Impression Scale, Communication Disorder, Controlled Study, Double Blind Procedure, Double-Blind Method, Female, Generalized Anxiety Disorder, Human, Impulsiveness, Lactobacillus Plantarum, Male, Physiology, Placebo, Placebos, Posttraumatic Stress Disorder, Probiotic Agent, Probiotics, Psychology, Questionnaires, Randomized Controlled Trial, Rating Scale, School Child, Scoring System, Social Behaviour, Social Interactions, Social Problem, Social Responsiveness Scale, Surveys, Swanson Nolan and Pelham IV Assessment, Synaptosomal Associated Protein 23, Taiwan},
pubstate = {published},
tppubtype = {article}
}

@article{Tan2016,
title = {Polyunsaturated fatty acids (PUFAs) for children with specific learning disorders},
author = {M L Tan and J J Ho and K H Teh},
url = {https://www.scopus.com/inward/record.uri?eid=2-s2.0-84988922340&doi=10.1002%2f14651858.CD009398.pub3&partnerID=40&md5=3460f403b8829b4692a0b6f795f4a2a3},
doi = {10.1002/14651858.CD009398.pub3},
issn = {1469493X},
year = {2016},
date = {2016-01-01},
journal = {Cochrane Database of Systematic Reviews},
volume = {2016},
number = {9},
publisher = {John Wiley and Sons Ltd},
abstract = {Background: About 5% of school children have a specific learning disorder, defined as unexpected failure to acquire adequate abilities in reading, writing or mathematics that is not a result of reduced intellectual ability, inadequate teaching or social deprivation. Of these events, 80% are reading disorders. Polyunsaturated fatty acids (PUFAs), in particular, omega-3 and omega-6 fatty acids, which normally are abundant in the brain and in the retina, are important for learning. Some children with specific learning disorders have been found to be deficient in these PUFAs, and it is argued that supplementation of PUFAs may help these children improve their learning abilities. Objectives: 1. To assess effects on learning outcomes of supplementation of polyunsaturated fatty acids (PUFAs) for children with specific learning disorders.2. To determine whether adverse effects of supplementation of PUFAs are reported in these children. Search methods: In November 2015, we searched CENTRAL, Ovid MEDLINE, Embase, PsycINFO, 10 other databases and two trials registers. We also searched the reference lists of relevant articles. Selection criteria: Randomised controlled trials (RCTs) or quasi-RCTs comparing PUFAs with placebo or no treatment in children younger than 18 years with specific learning disabilities, as diagnosed in accordance with the fifth (or earlier) edition of theDiagnostic and Statistical Manual of Mental Disorders (DSM-5), or the 10th (or earlier) revision of the International Classification of Diseases (ICD-10) or equivalent criteria. We included children with coexisting developmental disorders such as attention deficit hyperactivity disorder (ADHD) or autism. Data collection and analysis: Two review authors (MLT and KHT) independently screened the titles and abstracts of articles identified by the search and eliminated all studies that did not meet the inclusion criteria. We contacted study authors to ask for missing information and clarification, when needed. We used the GRADE approach to assess the quality of evidence. Main results: Two small studies involving 116 children, mainly boys between 10 and 18 years of age, met the inclusion criteria. One study was conducted in a school setting, the other at a specialised clinic. Both studies used three months of a combination of omega-3 and omega-6 supplements as the intervention compared with placebo. Although both studies had generally low risk of bias, we judged the risk of reporting bias as unclear in one study, and as high in the other study. In addition, one of the studies was funded by industry and reported active company involvement in the study. None of the studies reported data on the primary outcomes of reading, writing, spelling and mathematics scores, as assessed by standardised tests. Evidence of low quality indicates that supplementation of PUFAs did not increase the risk of gastrointestinal disturbances (risk ratio 1.43, 95% confidence interval 0.25 to 8.15; two studies, 116 children). Investigators reported no other adverse effects. Both studies reported attention deficit hyperactivity disorder (ADHD)-related behaviour outcomes. We were unable to combine the results in a meta-analysis because one study reported findings as a continuous outcome, and the other as a dichotomous outcome. No other secondary outcomes were reported. We excluded one study because it used a cointervention (carnosine), and five other studies because they did not provide a robust diagnosis of a specific learning disorder. We identified one ongoing study and found three studies awaiting classification. Authors' conclusions: Evidence is insufficient to permit any conclusions about the effect of PUFAs on the learning abilities of children with specific learning disorders. Well-designed RCTs with clearly defined populations of children with specific learning disorders who have been diagnosed by standardised diagnostic criteria are needed. © 2016 The Cochrane Collaboration.},
note = {cited By 6},
keywords = {Attention Deficit Disorder, Autism, Carnosine, Children, Diet Supplementation, Drug Effect, Gastrointestinal Symptom, Human, Learning Disorder, Meta Analysis, Outcome Assessment, Placebo, Polyunsaturated Fatty Acid, Priority Journal, Randomized Controlled Trial, Review, Systematic Review},
pubstate = {published},
tppubtype = {article}
}